Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

189.69USD
2 Dec 2016
Change (% chg)

$-0.68 (-0.36%)
Prev Close
$190.37
Open
$190.00
Day's High
$191.21
Day's Low
$188.93
Volume
836,319
Avg. Vol
937,220
52-wk High
$322.66
52-wk Low
$184.58

Latest Key Developments (Source: Significant Developments)

Urogen Pharma announces agreement to license RTGEL for use with Neurotoxins to Allergan
Friday, 14 Oct 2016 07:00am EDT 

Allergan Plc : Press release - Urogen Pharma announces agreement to license RTGEL™ for use with Neurotoxins to Allergan .Urogen Pharma - Allergan to make upfront payment of $17.5 million, as well as potential development and commercial milestones and royalties on net sales.  Full Article

Allergan says FDA accepts supplemental new drug application for avycaz
Tuesday, 11 Oct 2016 08:01am EDT 

Allergan Plc: FDA accepts supplemental new drug application (SNDA) for avycaz® (ceftazidime and avibactam) . Allergan plc - FDA is expected to take action on filing in q1 of 2017. . Allergan - application seeks to expand avycaz label to include phase 3 clinical data for treatment of complicated urinary tract infections .Allergan plc - application included results from a phase 3 study evaluating efficacy and safety of avycaz for treatment of patients with cuti.  Full Article

Allergan Plc enters licensing agreement with Astrazeneca for worldwide rights to Medi2070
Monday, 3 Oct 2016 02:00am EDT 

Allergan Plc : In addition, Allergan may make potential payments to astrazeneca of up to $1.27 billion, payable over a period of up to 15 years . Says Medimmune will continue ongoing medi2070 phase iia study in crohn's disease to completion . Potential payments include launch milestone payments of up to $435 million and sales-based milestone payments of $725 million . Allergan plc enters into licensing agreement with astrazeneca to obtain worldwide rights to medi2070 inflammatory disorder development program . Allergan will make an upfront payment to astrazeneca of $250 million for exclusive, worldwide license to develop and commercialize medi2070 .Says medimmune will transition phase IIb study in crohn's disease to allergan for completion.  Full Article

Allergan says egregious price hikes by "outlier" companies hurting venture capital investment
Tuesday, 6 Sep 2016 11:14am EDT 

Allergan CEO, in interview: Says Allergan aims to limit annual price increases of branded therapeutic drugs to low to mid single digit percentage range, slightly above current annual rate of inflation . Says Allergan's planned price increase limits would be similar to company's price increases seen in 2016, and should follow in 2017, beyond . Says Hillary Clinton's plan for oversight panels to monitor, punish drugmakers that impose unreasonable price increases on life-saving drugs impractical in free market system . Says Clinton's proposal for emergency imports of drugs to ease drug shortages, prices could subject U.S. public to lower safety standards . Says publicity from "egregious" price increases of other companies have caused shrinkage of venture capital investment in new drugs .Says "outlier" companies that have drawn criticism for price hikes are endangering overall industry research and development.  Full Article

Allergan acquires gene therapy company Retrosense Therapeutics
Tuesday, 6 Sep 2016 08:00am EDT 

Allergan Plc : Allergan Acquires Gene Therapy Company Retrosense Therapeutics Adding First-In-Class technology to company's innovative eye care pipeline . Says under terms of transaction, Allergan has paid Retrosense a $60 million upfront payment . Says also has agreed to potential regulatory and commercialization milestone payments related to rst-001 .Says acquired substantially all of assets of Retrosense in an all-cash transaction.  Full Article

Allergan and Adamas enter settlement with Amneal Pharmaceuticals
Wednesday, 31 Aug 2016 08:00am EDT 

Allergan Plc : Allergan and Adamas announce settlement with Amneal related to namzaric patent litigation . Adamas will grant amneal a license to market generic versions of namzaric beginning on January 1, 2025 . Other terms of settlement were not disclosed . Under certain circumstances, amneal has an option to launch an authorized generic version of namzaric beginning on January 1, 2026 . Settlement provides additional clarity for patent-protected life of namzaric .Alternatively, under certain circumstances, amneal has option to launch authorized generic version of namzaric beginning on January 1, 2026.  Full Article

Allergan to acquire eye care company Forsight Vision5
Thursday, 11 Aug 2016 08:00am EDT 

Allergan PLC : Allergan to acquire eye care company Forsight Vision5 adding Peri-Ocular Ring Technology to company's leading portfolio of innovative eye health products . Under terms of agreement, Allergan will acquire Forsight Vision5 for a $95 million upfront payment and a launch milestone payment .Transaction is expected to be completed within 60 days.  Full Article

Allergan Equico reports 9.9 pct stake in Teva Pharmaceutical
Monday, 8 Aug 2016 06:15pm EDT 

Allergan :Reports a stake of 9.9 pct in Teva Pharmaceutical Industries Ltd as of July 27, 2016 - SEC filing.  Full Article

Allergan reports Q2 non-GAAP earnings per share of $3.35
Monday, 8 Aug 2016 07:00am EDT 

Allergan Plc : Allergan reports strong second quarter 2016 continuing operations performance with net revenues of $3.7 billion . Q2 revenue $3.7 billion . Company updates full-year 2016 continuing operations guidance . Q2 non-GAAP earnings per share $3.35 . Q2 loss per share $1.25 from continuing operations . Q2 earnings per share view $3.34 -- Thomson Reuters I/B/E/S . Sees full year GAAP and non-GAAP total reported net revenue $14.65 billion - $14.90 billion . Sees FY total branded net revenue $14.75 bln - $15 bln . Sees FY 2016 GAAP loss per share $1.95 - $2.15; sees FY 2016 non-GAAP earnings per share $13.75 - $14.20 . FY 2016 earnings per share view $14.19 -- Thomson Reuters I/B/E/S .Total net revenues in quarter were impacted by "loss of exclusivity on Namenda IR".  Full Article

Allergan Q2 non-GAAP earnings per share $3.35
Monday, 8 Aug 2016 07:00am EDT 

Allergan Plc : Allergan reports strong second quarter 2016 continuing operations performance with net revenues of $3.7 billion . Q2 non-GAAP earnings per share $3.35 . Q2 loss per share $1.25 from continuing operations . Q2 revenue $3.7 billion versus i/b/e/s view $4.08 billion . Q2 earnings per share view $3.34 -- Thomson Reuters I/B/E/S . GAAP total reported net revenues $14.65 billion - $14.90 billion . Total net revenues in quarter were impacted by "loss of exclusivity on Namenda IR" . Company updates full-year 2016 continuing operations guidance . Sees full-year total branded net revenue $14.75 billion- $15 billion . Sees 2016 GAAP loss per share of $1.95 - $2.15; sees 2016 non GAAP earnings per share of $13.75 - $14.20 .Full-year 2016 earnings per share view $14.19, revenue view $16.61 billion -- Thomson Reuters I/B/E/S.  Full Article

Photo

Amgen, Allergan apply for European nod for Avastin biosimilar

Amgen Inc and Allergan Plc said they have submitted an application to the European health regulator seeking approval of their biosimilar version of Roche Holding AG's blockbuster cancer treatment, Avastin.